Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in hemodialysis patients treated with different membranes

被引:108
作者
Memoli, B
Minutolo, R
Bisesti, V
Postiglione, L
Conti, A
Marzano, L
Capuano, A
Andreucci, M
Balletta, MM
Guida, B
Tetta, C
机构
[1] Univ Naples Federico II, Dept Nephrol, I-80121 Naples, Italy
[2] Univ Naples Federico II, Dept Cellular & Mol Biol, I-80121 Naples, Italy
[3] Univ Naples Federico II, Dept Physiol, Nutr Sect, I-80121 Naples, Italy
[4] Bellco Clin & Res Dept, Mirandola, Italy
[5] Hosp Scafati, Div Nephrol, Scafati, Italy
[6] Hosp Avellino, Div Nephrol, Avellino, Italy
[7] Hosp Eboli, Div Nephrol, Eboli, Italy
[8] Hosp Salerno, Div Nephrol, Salerno, Italy
[9] Hosp Naples, Div Nephrol, Naples, Italy
[10] Pellegrini Hosp, Naples, Italy
关键词
serum albumin; biocompatibility; interleukin-6 (IL-6); C-reactive protein (CRP); dialysis membranes;
D O I
10.1053/ajkd.2002.30545
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Protein malnutrition, a condition associated with an albumin concentration less than 3.5 g/dL, has been shown to be a major risk factor for Increased mortality In hemodialysis patients. The aim of this cross-over study was to evaluate the relationship between the type of membrane adopted and serum albumin changes by measuring peripheral blood mononuclear cells (PBMC) interleukin-6 (IL-6) release, serum albumin, and plasma concentrations of C-reactive protein (CRP) in 18 patients dialyzed with different membranes. During the study, all patients were dialyzed with cuprophan (CU), synthetically modified cellulosic (SMC) membrane (a new cellulosic membrane with lesser complement activation), and cellulose diacetate (CD) membrane, and have served as their own controls. IL-6 spontaneous release by PBMC resulted after 3 months of SMC (436.2 +/- 47.4 pg/mL) significantly (P < 0.05) reduced as compared with CU (569.3 +/- 24.5 pg/mL). This effect was more evident after 6 months of dialysis with SMC (220 +/- 35.3 pg/mL, P < 0.01 versus CU and versus 3 months of SMC). The passage to CD membrane was followed by a progressive new increase in the IL-6 PBMC release (332.3 +/- 30.7 after 3 months, and 351.2 +/- 35.8 pg/mL after 6 months, respectively) that, however, remained significantly (P < 0.05) lower than CU. The behavior of CRP plasma levels resembled that of IL-6 PBMC release (23.3 +/- 4.7 In CU, 11.0 +/- 2.1 after 3 months in SMC, and 7.9 +/- 1.5 after 6 months In SMC, respectively). IL-6 release values were positively correlated with circulating levels of CRP (r = 0.3264, P < 0.002). Serum albumin increased after 6 months of dialysis with SMC membranes (3.25 +/- 0.09 g/dL In CU and 3.64 +/- 0.07 g/dL in SMC, P < 0.05). When the patients were switched to CD, serum albumin showed a slight, though not statistically significant, decrease. Serum albumin concentrations negatively correlated with both IL-6 release values (r = -0.247, P < 0.05) and CRP plasma levels (r = -0.433, P < 0.001). In conclusion, our data clearly show that a significant relationship exists between biocompatibility of the membranes and serum albumin changes; serum albumin levels, in fact, are negatively correlated with the PBMC spontaneous IL-6 release values and CRP circulating levels. (C) 2002 by the National Kidney Foundation, Inc.
引用
收藏
页码:266 / 273
页数:8
相关论文
共 40 条
[1]   ACTION OF RECOMBINANT HUMAN INTERLEUKIN-6, INTERLEUKIN-1-BETA AND TUMOR NECROSIS FACTOR-ALPHA ON THE MESSENGER-RNA INDUCTION OF ACUTE-PHASE PROTEINS [J].
ANDUS, T ;
GEIGER, T ;
HIRANO, T ;
KISHIMOTO, T ;
HEINRICH, PC .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1988, 18 (05) :739-746
[2]  
[Anonymous], USRDS 1998 ANN DAT R
[3]   Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients [J].
Bologa, RM ;
Levine, DM ;
Parker, TS ;
Cheigh, JS ;
Serur, D ;
Stenzel, KH ;
Rubin, AL .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (01) :107-114
[4]   Synthetically modified cellulose (SMC) - A cellulosic hemodialysis membrane with minimized complement activation [J].
Bowry, SK ;
Rintelen, TH .
ASAIO JOURNAL, 1998, 44 (05) :M579-M583
[5]   Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients [J].
Cheung, AK ;
Sarnak, MJ ;
Yan, GF ;
Dwyer, JT ;
Heyka, RJ ;
Rocco, MV ;
Teehan, BP ;
Levey, AS .
KIDNEY INTERNATIONAL, 2000, 58 (01) :353-362
[6]  
DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205
[7]  
Depner TA, 1996, J AM SOC NEPHROL, V7, P780
[8]   Effect of the dialysis membrane on mortality of chronic hemodialysis patients [J].
Hakim, RM ;
Held, PJ ;
Stannard, DC ;
Wolfe, RA ;
Port, FK ;
Daugirdas, JT ;
Agodoa, L .
KIDNEY INTERNATIONAL, 1996, 50 (02) :566-570
[9]   The dose of hemodialysis and patient mortality [J].
Held, PJ ;
Port, FK ;
Wolfe, RA ;
Stannard, DC ;
Carroll, CE ;
Daugirdas, JT ;
Bloembergen, WE ;
Greer, JW ;
Hakim, RM .
KIDNEY INTERNATIONAL, 1996, 50 (02) :550-556
[10]   Synthetically modified cellulose: an alternative to synthetic membranes for use in haemodialysis? [J].
Hoenich, NA ;
Woffindin, C ;
Stamp, S ;
Roberts, SJ ;
Turnbull, J .
BIOMATERIALS, 1997, 18 (19) :1299-1303